November 7, 2019
NEWS RELEASE
Company:
Representative:

Contact:Telephone:KYORIN Holdings, Inc.
Yutaka Ogihara
Representative Director, President(Securities Code: 4569, TSE 1st Sec.)
Yoshinori Tanifuji
Director, Corporate Planning(0)3-3525-4707

KYORIN and JEIL Signed License Agreement for Vibegron in Korea
KYORIN Holdings, Inc. today announced that its wholly owned subsidiary of KYORIN PharmaceuticalCo., Ltd. (Head office: Chiyoda-ku, Tokyo, President & CEO: Shigeru Ogihara, "Kyorin") signed alicense agreement with JEIL Pharmaceutical Co., Ltd. (Head office: Seoul, Korea, President & CEO: SukJe, Sung, "JEIL") to grant to JEIL an exclusive license to develop, manufacture and commercialize
vibegron, an overactive bladder (OAB) therapeutic agent, in Korea.
Vibegron is a novel once-daily β3-adrenergic receptor agonist that was discovered by Merck & Co., Inc.,
Kenilworth, N.J., U.S.A., known as MSD outside the United States and Canada ("Merck"). It acts
selectively on the bladder's β3-adrenergic receptor, relaxes the bladder and enhances the urine collection,and consequently improves the symptoms of urgency, urinary frequency and urge urinary incontinence
associated with OAB.
Kyorin acquired from Merck an exclusive license to develop, manufacture and commercialize vibegron inJapan in July 2014 and later expanded the license territory to certain other Asian countries1 in April 2017.
In Japan, Kyorin developed this agent with Kissei Pharmaceutical Co., Ltd. under a co-development andco-marketing agreement entered into as of March 2016, and the companies have been co-marketing thesame under the brand name of "Beova® Tablets 50mg" since November 2018.
Kyorin is committed to prevailing vibegron into Japanese market and contributing to improve the QOL ofpatients suffering from OAB symptoms. The partnership with JEIL will allow Kyorin to promote thepenetration of vibegron in the Korean market as well and accelerate its global business expansion.
The impact of this transaction is reflected in the revised financial forecast for the fiscal year ending March
31, 2020 announced today.
###1

Korea, Taiwan, Hong Kong and ten member states of ASEAN

About JEIL Pharmaceutical Co., Ltd.
Foundation:
March 1959
President & CEO:Suk Je, Sung
Annual Sales:
KRW630 billion (USD560 million) (2018)
Employees:
970 (as of December 31, 2018)
Overview:
Pursuing happiness and health for people worldwide, JEIL Pharmaceutical grows
into a global company providing innovative and integrated health care solution.
JEIL Pharmaceutical has engaged in strategic partnership with global
pharmaceutical companies to provide the domestic market with outstanding newdrugs. With accumulated experiences and networks, JEIL has been expanding
business in various therapeutic category areas such as Cardiology, Urology,
Gastrointestinal, Oncology and etc. In addition, JEIL has been striving tocontribute to unmet medical needs as focusing R&D in Oncology and Psychiatry.
About KYORIN Pharmaceutical Co., Ltd.
Foundation:
December 1923
President & CEO:
Shigeru Ogihara
Annual Sales:
JPY 99.736 billion (FY ending on March 31, 2019)
Employees:
1,567 (as of March 31, 2019)
Overview:
Trusted among patients and professionals in the medical industry, KYORIN
Pharmaceutical strives to be a company that contributes to the public health and isrecognized as a one with social significance by improving its presence in thespecific therapeutic areas and through global discovery of novel drugs. KYORIN
Pharmaceutical uses franchise customer strategy where its marketing efforts arefocused on respiratory medicine, otolaryngology and urology. In drug discovery,
it is deploying 'selection and concentration' and promoting activities aimed at
first-in-class drug discovery, such as actively searching for and introducing
external drug discovery themes as well as multi-tiered program development.